[Drug-eluting stents in coronary arteries]
The Swedish Council on Health Technology Assessment (SBU)
Record ID 32010001105
Swedish
Authors' recommendations:
Compared with bare metal mesh stents, drug-eluting stents prevent the recurrence of narrowing of the coronary artery, without increasing the risk of complications. This applies to both stable and unstable coronary artery disease.
Various drug-eluting stents may differ in both effect and risks:
Everolimus-eluting stents give rise to fewer stent thromboses than sirolimus-eluting stents, and fewer myocardial infarctions and stent thromboses than paclitaxel-eluting stents.
However, in comparative studies, there seem to be no differences in safety or effect of everolimus-, biolimus- or second-generation zotarolimus-eluting stents.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.sbu.se/201406e
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Sweden
MeSH Terms
- Coronary Vessels
- Drug Delivery Systems
Contact
Organisation Name:
Swedish Agency for Health Technology Assessment and Assessment of Social Services
Contact Address:
P.O. Box 3657, SE-103 59 Stockholm, Sweden. Tel: +46 8 4123200, Fax: +46 8 4113260
Contact Name:
registrator@sbu.se
Contact Email:
registrator@sbu.se
Copyright:
The Swedish Council on Health Technology Assessment (SBU)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.